#pkmodeling search results
A new study demonstrates how exposure-response modeling can be used to determine the optimal dose of pemigatinib for the treatment of cholangiocarcinoma: ➡ bit.ly/49IPmWG #Pharmacokinetic #PKmodeling @ASCPT_ClinPharm
Neutralizing ADA = noisy data. Don’t let it cloud your PK insights. Join our webinar to see how Certara scientists model ADA-driven variability for better dose prediction—across species. Actionable tips + Phoenix® NLME in action. Register: certara.com/webinar/pharma… #ADA #PKModeling
Congratulations to post-doc trainee Dr. Chimeddulam Dalaijamts! She has accepted a Senior Analyst position at Intercept Pharmaceuticals - she'll be doing what she loves most - PK modeling in clinical pharmacology. @SRP_NIEHS @tamuvetmed #pkmodeling
Check out our blog post from earlier this month, "An In-Depth Guide to Pharmacokinetic Modeling." hubs.li/Q01wjq400 #pkmodeling #biotech #drugdevelopment
Pleased to share that VeriSIM Life CSO Dr. Szczepan Baran is a member of the NIH working group on Novel Alternative Models, advising on reducing/refining animal studies in drug research. #AI #AnimalResearch #pkmodeling hubs.li/Q01BfzGq0
Quantifying how a drug moves into, through, and out of the body is at the heart of pharmacokinetic modeling (PK), helping inform many aspects of the drug development process. Read our latest blog post to learn more: bit.ly/3UTtE9K #pkmodeling #biotech #drugdevelopment
Which #PKmodeling approach is right for your program? Our latest blog compares NCA, PopPK/PD, and PBPK modeling—highlighting when to use each for maximum impact in MIDD: bit.ly/4fzp1xh #PremierResearch #ModelInformedDrugDevelopment
Excited to talk @AdeliadePharmacology Scientific meeting #research .Personalised therapy is the key to mitigate risks with HRT. Enjoyed listening to other amazing speakers, as well. @PIDG_UniSA @UniversitySA @UniSACRI #3Dprinting #pkmodeling #womenshealth
Join me at ACCP (WA) on 9/11 for Symposium 7; 1:30-5 pm. Excited to present the results of our recent analysis on PK modeling in FIH dose selection of IO products. Don't miss out on this opportunity to learn about our findings. #ACCP2023 #oncology #PKModeling #FIHdoseselection
Our Pediatric Early Development Symposium is a can’t miss event featuring engaging & educational sessions like Pharmacokinetic Modeling, which will address questions like: How are PBPK & PopPK models qualified/validated? Register today buff.ly/389Dxds #pkmodeling #pkdata
Check out my former-labmate/mentor/therapist Dr. Naveen Mehta's excellent work published in @natBME nature.com/articles/s4155…. Main takeaway: when designing cancer vaccines, don't forget to consider their pharmacokinetics--it makes a difference! #ProteinEngineering #PKmodeling
Open for a LTD time only - articles from themed Issue on #Nanomedicine from #PKmodeling to tox effects bit.ly/1MuW3fV
Which #PKmodeling approach is right for your program? Our latest blog compares NCA, PopPK/PD, and PBPK modeling—highlighting when to use each for maximum impact in MIDD: bit.ly/4fzp1xh #PremierResearch #ModelInformedDrugDevelopment
Neutralizing ADA = noisy data. Don’t let it cloud your PK insights. Join our webinar to see how Certara scientists model ADA-driven variability for better dose prediction—across species. Actionable tips + Phoenix® NLME in action. Register: certara.com/webinar/pharma… #ADA #PKModeling
Join me at ACCP (WA) on 9/11 for Symposium 7; 1:30-5 pm. Excited to present the results of our recent analysis on PK modeling in FIH dose selection of IO products. Don't miss out on this opportunity to learn about our findings. #ACCP2023 #oncology #PKModeling #FIHdoseselection
Pleased to share that VeriSIM Life CSO Dr. Szczepan Baran is a member of the NIH working group on Novel Alternative Models, advising on reducing/refining animal studies in drug research. #AI #AnimalResearch #pkmodeling hubs.li/Q01BfzGq0
Check out our blog post from earlier this month, "An In-Depth Guide to Pharmacokinetic Modeling." hubs.li/Q01wjq400 #pkmodeling #biotech #drugdevelopment
Quantifying how a drug moves into, through, and out of the body is at the heart of pharmacokinetic modeling (PK), helping inform many aspects of the drug development process. Read our latest blog post to learn more: bit.ly/3UTtE9K #pkmodeling #biotech #drugdevelopment
Congratulations to post-doc trainee Dr. Chimeddulam Dalaijamts! She has accepted a Senior Analyst position at Intercept Pharmaceuticals - she'll be doing what she loves most - PK modeling in clinical pharmacology. @SRP_NIEHS @tamuvetmed #pkmodeling
Excited to talk @AdeliadePharmacology Scientific meeting #research .Personalised therapy is the key to mitigate risks with HRT. Enjoyed listening to other amazing speakers, as well. @PIDG_UniSA @UniversitySA @UniSACRI #3Dprinting #pkmodeling #womenshealth
Our Pediatric Early Development Symposium is a can’t miss event featuring engaging & educational sessions like Pharmacokinetic Modeling, which will address questions like: How are PBPK & PopPK models qualified/validated? Register today buff.ly/389Dxds #pkmodeling #pkdata
Check out my former-labmate/mentor/therapist Dr. Naveen Mehta's excellent work published in @natBME nature.com/articles/s4155…. Main takeaway: when designing cancer vaccines, don't forget to consider their pharmacokinetics--it makes a difference! #ProteinEngineering #PKmodeling
Open for a LTD time only - articles from themed Issue on #Nanomedicine from #PKmodeling to tox effects bit.ly/1MuW3fV
Congratulations to post-doc trainee Dr. Chimeddulam Dalaijamts! She has accepted a Senior Analyst position at Intercept Pharmaceuticals - she'll be doing what she loves most - PK modeling in clinical pharmacology. @SRP_NIEHS @tamuvetmed #pkmodeling
A new study demonstrates how exposure-response modeling can be used to determine the optimal dose of pemigatinib for the treatment of cholangiocarcinoma: ➡ bit.ly/49IPmWG #Pharmacokinetic #PKmodeling @ASCPT_ClinPharm
Neutralizing ADA = noisy data. Don’t let it cloud your PK insights. Join our webinar to see how Certara scientists model ADA-driven variability for better dose prediction—across species. Actionable tips + Phoenix® NLME in action. Register: certara.com/webinar/pharma… #ADA #PKModeling
Pleased to share that VeriSIM Life CSO Dr. Szczepan Baran is a member of the NIH working group on Novel Alternative Models, advising on reducing/refining animal studies in drug research. #AI #AnimalResearch #pkmodeling hubs.li/Q01BfzGq0
Check out our blog post from earlier this month, "An In-Depth Guide to Pharmacokinetic Modeling." hubs.li/Q01wjq400 #pkmodeling #biotech #drugdevelopment
Quantifying how a drug moves into, through, and out of the body is at the heart of pharmacokinetic modeling (PK), helping inform many aspects of the drug development process. Read our latest blog post to learn more: bit.ly/3UTtE9K #pkmodeling #biotech #drugdevelopment
Excited to talk @AdeliadePharmacology Scientific meeting #research .Personalised therapy is the key to mitigate risks with HRT. Enjoyed listening to other amazing speakers, as well. @PIDG_UniSA @UniversitySA @UniSACRI #3Dprinting #pkmodeling #womenshealth
Which #PKmodeling approach is right for your program? Our latest blog compares NCA, PopPK/PD, and PBPK modeling—highlighting when to use each for maximum impact in MIDD: bit.ly/4fzp1xh #PremierResearch #ModelInformedDrugDevelopment
Something went wrong.
Something went wrong.
United States Trends
- 1. Jokic 25.6K posts
- 2. Lakers 52.7K posts
- 3. Epstein 1.67M posts
- 4. #AEWDynamite 50.2K posts
- 5. #River 5,046 posts
- 6. Nemec 3,339 posts
- 7. Clippers 14.5K posts
- 8. Shai 16.3K posts
- 9. #ReasonableDoubtHulu N/A
- 10. Thunder 40.9K posts
- 11. #NJDevils 3,114 posts
- 12. Markstrom 1,256 posts
- 13. #Blackhawks 1,602 posts
- 14. Ty Lue 1,146 posts
- 15. Nemo 8,582 posts
- 16. Mikey 71.8K posts
- 17. Lafferty N/A
- 18. Rory 8,055 posts
- 19. Joker 26.6K posts
- 20. Jordan Miller N/A